These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7705673)

  • 1. A phase I trial of cyclosphosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer.
    Speyer JL; Mandeli J; Hochster H; Runowicz C; Wadler S; Wallach R; Cohen C; Oette D; Sorich J; Demakos E
    Gynecol Oncol; 1995 Mar; 56(3):387-94. PubMed ID: 7705673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.
    Veldhuis GJ; Willemse PH; van Gameren MM; Aalders JG; Mulder NH; Mull B; Biesma B; de Vries EG
    J Clin Oncol; 1995 Mar; 13(3):733-40. PubMed ID: 7884433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
    Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
    Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor.
    Rusthoven J; Levin L; Eisenhauer E; Mazurka J; Carmichael J; O'Connell G; Bryson P; Hirte H; Koski B
    J Natl Cancer Inst; 1991 Dec; 83(23):1748-53. PubMed ID: 1770554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma.
    Hofstra LS; Kristensen GB; Willemse PH; Vindevoghel A; Meden H; Lahousen M; Oberling F; Sorbe B; Crump M; Sklenar I; Sluiter WJ; Kiese B; Trope CG; de Vries EG
    J Clin Oncol; 1998 Oct; 16(10):3335-44. PubMed ID: 9779710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer.
    Biesma B; Willemse PH; Mulder NH; Sleijfer DT; Gietema JA; Mull R; Limburg PC; Bouma J; Vellenga E; de Vries EG
    Blood; 1992 Sep; 80(5):1141-8. PubMed ID: 1515636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study.
    D'Hondt V; Humblet Y; Guillaume T; Baatout S; Chatelain C; Berlière M; Longueville J; Feyens AM; de Greve J; Van Oosterom A
    Blood; 1995 May; 85(9):2347-53. PubMed ID: 7537110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.
    Miller LL; Korn EL; Stevens DS; Janik JE; Gause BL; Kopp WC; Holmlund JT; Curti BD; Sznol M; Smith JW; Urba WJ; Donegan SE; Watson TM; Longo DL
    Blood; 1999 May; 93(10):3250-8. PubMed ID: 10233876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.
    D'Hondt V; Weynants P; Humblet Y; Guillaume T; Canon JL; Beauduin M; Duprez P; Longueville J; Müll R; Chatelain C
    J Clin Oncol; 1993 Nov; 11(11):2063-71. PubMed ID: 8229120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.
    Reed E; Janik J; Bookman MA; Rothenberg M; Smith J; Young RC; Ozols RF; VanderMolen L; Kohn E; Jacob JL
    J Clin Oncol; 1993 Nov; 11(11):2118-26. PubMed ID: 8229126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer.
    Vadhan-Raj S; Kudelka AP; Garrison L; Gano J; Edwards CL; Freedman RS; Kavanagh JJ
    J Clin Oncol; 1994 Apr; 12(4):707-14. PubMed ID: 8151314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
    de Vries EG; Biesma B; Willemse PH; Mulder NH; Stern AC; Aalders JG; Vellenga E
    Cancer Res; 1991 Jan; 51(1):116-22. PubMed ID: 1988077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer.
    Runowicz CD; Mandeli J; Speyer JL; Wadler S; Hochster H; Garrison L; Holland JF
    Am J Obstet Gynecol; 1996 Apr; 174(4):1151-9; discussion 1159-60. PubMed ID: 8623842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficiency, safety and tolerability of recombinant human interleukin-3 (rhIL-3) as supportive therapy accompanying dose-intensive carboplatin containing chemotherapy in ovarian cancer with special regard to thrombocytopenia].
    Meden H; Fock M; Krauss T; Kuhn W
    Zentralbl Gynakol; 1999; 121(8):375-83. PubMed ID: 10486880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical study on the effects of recombinant human interleukin-3 on thrombocytopenia after chemotherapy for advanced ovarian cancer. SDZ ILE 964 [IL-3] Study Group.
    Yamamoto K; Yajima A; Terashima Y; Nozawa S; Taketani Y; Yakushiji M; Noda K
    J Immunother; 1999 Nov; 22(6):539-45. PubMed ID: 10570752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.
    Fennelly D; Schneider J; Spriggs D; Bengala C; Hakes T; Reich L; Barakat R; Curtin J; Moore MA; Hoskins W
    J Clin Oncol; 1995 May; 13(5):1160-6. PubMed ID: 7537799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
    Dercksen MW; Hoekman K; ten Bokkel Huinink WW; Rankin EM; Dubbelman R; van Tinteren H; Wagstaff J; Pinedo HM
    Br J Cancer; 1993 Nov; 68(5):996-1003. PubMed ID: 7692922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study.
    Calvert AH; Lind MJ; Ghazal-Aswad S; Gumbrell L; Millward MJ; Bailey NP; Doré-Green F; Chapman F; Simmons D; Proctor M
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):1-6. PubMed ID: 7527590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.